Loading stock data…
CERS
$2.72+0.69 (+33.99%)
Market ClosedLast close May 1
Cerus Corporation operates as a biomedical products company.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cerus Corporation in the Healthcare sector is trading at $2.72. The stock is currently 14% below its 52-week high of $3.15, remaining 52.0% above its 200-day moving average. Technical signals show overbought RSI of 80 and bullish MACD crossover, explaining why CERS maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 80) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.72
Potential Upside
5%
Whystock Fair Value$2.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$365.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.33%
Volume
Today's trading volume
24.85M
Recent News
Cerus Corporation Q1 2026 Earnings Call Summary
Moby summary of Cerus Corporation's Q1 2026 earnings call
Cerus Corp (CERS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Cerus Corp (CERS) reports a 24% increase in product revenue and raises full-year guidance, despite facing logistical challenges and competitive pressures.
Cerus (CERS) Q1 2026 Earnings Transcript
With me on the call are Obi Greenman, Cerus Corporation’s president and chief executive officer; Vivek K. Jayaraman, Cerus Corporation’s chief operating officer, incoming president and chief executive officer; and Kevin D. Green, Cerus Corporation’s chief financial officer. Cerus Corporation issued a press release today announcing our financial results for the first quarter ended March 31, 2026, the company's recent business highlights, and outlook.
Cerus Q1 Earnings Call Highlights
Cerus (NASDAQ:CERS) reported first-quarter 2026 product revenue of $53.7 million, up 24% from the prior-year period, as management pointed to continued strength in its global INTERCEPT platelet franchise and accelerating demand for its INTERCEPT Fibrinogen Complex (IFC) business in the United States
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and...